Corneal Endothelial Dystrophy Market Report 2026

The corneal endothelial dystrophy market size has grown strongly in recent years. It will grow from $184.84 billion in 2025 to $199.77 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to genetic prevalence of corneal disorders, limited early detection options, reliance on surgical intervention, aging population growth, specialized hospital-based treatment.

The corneal endothelial dystrophy market size is expected to see strong growth in the next few years. It will grow to $269.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in corneal imaging, increasing access to eye care, growth of specialty eye clinics, improved awareness of rare eye diseases, innovation in corneal therapies. Major trends in the forecast period include rising adoption of advanced corneal diagnostics, increased use of minimally invasive treatments, growing focus on early genetic diagnosis, expansion of specialized ophthalmic care, improved surgical outcome monitoring.

The increasing demand for corneal transplantation is expected to support the growth of the corneal endothelial dystrophy market in the coming years. Corneal transplantation is a surgical procedure in which a damaged or diseased cornea is replaced with healthy donor tissue to restore vision and improve overall eye health. The rising demand for corneal transplants is driven by the growing prevalence of corneal disorders, advancements in surgical techniques, and improved rates of organ donation. Corneal endothelial dystrophy is commonly managed through corneal transplantation, which replaces the damaged endothelial layer with healthy donor cells to restore corneal transparency, reduce edema, and enhance visual function. For example, in 2023, according to the Eye Bank Association of America, a US-based transplant organization, the number of domestic keratoplasty procedures increased by 2.7%, rising from 49,597 procedures in 2022 to 50,925 procedures in 2023. Therefore, the growing demand for corneal transplantation is contributing to the expansion of the corneal endothelial dystrophy market.

Companies operating in the corneal endothelial dystrophy market are increasingly concentrating on the development of innovative therapies, such as allogeneic cell therapy, to address unmet clinical needs by offering advanced and minimally invasive treatment options that improve patient outcomes. Allogeneic cell therapy involves the use of cells obtained from a genetically distinct donor of the same species to treat a recipient. For instance, in September 2024, Aurion Biotech Inc., a US-based clinical-stage biotechnology company, launched Vyznova (neltependocel) in Japan for the treatment of bullous keratopathy, a condition associated with corneal endothelial disease. Vyznova is a cell-based therapy developed to restore damaged corneal endothelial cells that lead to vision impairment. It became the first approved cell therapy for corneal endothelial disease in Japan. The therapy uses laboratory-cultured corneal endothelial cells, enabling the production of up to 1,000 doses from a single donor. This approach offers a less invasive alternative to traditional corneal transplantation, helps mitigate donor cornea shortages, and provides a novel method for vision restoration in patients with corneal disorders.

In February 2024, Eversight, a US-based nonprofit eye bank, entered into a partnership with Emmecell. Through this collaboration, Eversight and Emmecell aim to advance minimally invasive cell-based therapies for the treatment of corneal endothelial diseases, including corneal edema resulting from endothelial cell dysfunction, and to broaden global access to innovative treatment options. Emmecell is a US-based biotechnology company focused on developing non-surgical cell therapies for corneal edema, a condition often caused by corneal endothelial dysfunction.

Major companies operating in the corneal endothelial dystrophy market are Abbvie (Allergan plc), Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co Ltd, Lumenis Ltd, Carl Zeiss Meditec AG, Keeler Limited, ProQR Therapeutics NV, Rugby Laboratories, Blumont Healthcare Ltd, Grevis Pharmaceuticals Pvt Ltd, Rayner Group, Trefoil Therapeutics, Design Therapeutics, Horus Pharma, Stealth BioTherapeutics Corp, Surrozen Inc, Price Vision Group LLC, Invirsa Inc, KeraMed Inc, Massachusetts Eye and Ear, MediciBIO Co LTD, Prime Medicine Inc, AJL Ophthalmic SA.

North America was the largest region in the corneal endothelial dystrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the corneal endothelial dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the corneal endothelial dystrophy market by increasing costs of imported diagnostic devices, surgical instruments, imaging systems, and consumables. Hospitals and ophthalmic clinics in North America and Europe are most affected due to reliance on imported equipment, while Asia-Pacific faces higher procurement costs. These tariffs are raising treatment expenses. However, they are also encouraging domestic device manufacturing and regional ophthalmic infrastructure development.

The corneal endothelial dystrophy market research report is one of a series of new reports that provides corneal endothelial dystrophy market statistics, including corneal endothelial dystrophy industry global market size, regional shares, competitors with a corneal endothelial dystrophy market share, detailed corneal endothelial dystrophy market segments, market trends and opportunities, and any further data you may need to thrive in the corneal endothelial dystrophy industry. This corneal endothelial dystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Corneal endothelial dystrophy is a hereditary eye condition that affects the corneal endothelium, which is the innermost layer of the cornea, resulting in a gradual loss of corneal transparency. The disorder is marked by the degeneration of endothelial cells that are essential for regulating fluid balance within the cornea.

The primary treatment options for corneal endothelial dystrophy include phototherapeutic keratectomy (PTK), amniotic membrane transplantation, anterior stromal puncture, and conjunctival flaps. PTK is a laser-based procedure used to remove superficial layers of the cornea to address surface irregularities or scarring. These treatment approaches are applied across different disease types, including congenital hereditary endothelial dystrophy type 1, congenital hereditary endothelial dystrophy type 2, posterior polymorphous corneal dystrophy, and Fuchs’ endothelial corneal dystrophy. Diagnostic methods involve corneal examination and grading, corneal tomography, corneal pachymetry, and corneal cell count. These treatments are provided across various healthcare settings, including hospitals, clinics, and other medical facilities.

The corneal endothelial dystrophy market consists of revenues earned by entities by providing services such as endothelial keratoplasty, specialized contact lenses, and penetrating keratoplasty. The market value includes the value of related goods sold by the service provider or included within the service offering. The corneal endothelial dystrophy market also includes sales of medications, corneal implants, surgical instruments, diagnostic devices, cell therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.